Business
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDTThe abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDTThe abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ETSOUTH SAN FRANCISCO, Calif., April 24, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that interim results from the investigator-sponsored Phase 2 trial evaluating darovasertib safety and efficacy as neoadjuvant/adjuvant treatment in uveal melanoma (UM) have been selected for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.\n\n \n \n \n \n \n \n\n \nDetails for the oral presentation are as follows:\nSession: Melanoma/ Skin Cancers\nTitle: A Phase 2 Safety and Efficacy Study of Neoadjuvant/Adjuvant Darovasertib for Localized Ocular Melanoma\nPresenter: Anthony Joshua, M.B.B.S, Ph.D., FRACP\nAbstract number: 9510\nDate and Time: June 3, 2024, at 9:51 AM CDT\nASCO will publish the abstract summary on Thursday, May 23, 2024, at approximately 5:00 pm ET.\nAbout IDEAYA Biosciences\nIDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.\nForward-Looking Statements\nThis press release contains forward-looking statements, including, but not limited to, statements related to the timing and content of future press releases. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of ...